Missouri AG orders Eli Lilly to stop demanding hospital data for 340B discounts
Missouri Attorney General Catherine Hanaway sent a cease‑and‑desist letter to Eli Lilly on Oct 26, demanding the company stop requiring hospitals to submit claims data as a condition for receiving 340B discounted drugs.
The AG alleges Lilly broke its promise to provide 340B pricing to eligible hospitals and made false or misleading statements, violating state law.
Hanaway points to University of Missouri Health Care, which reportedly agreed to provide data but was still denied discounts, and she has asked Lilly to end the policy by Nov 26.
The move reflects a broader trend of states challenging drugmakers' practices around the 340B program, potentially reshaping how companies handle pricing and data requirements for discounted medicines.
This writeup was produced by pharmadog from original reporting by STAT.
Original headline: “STAT+: Missouri AG warns Lilly to stop requiring data from hospitals seeking 340B drug discounts”
read at STAT ↗
comments(0)
5-min edit window · permanent after that